|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
LU86084A1
(fr)
|
1985-09-20 |
1987-04-02 |
Faco Sa |
Apparei de massage electrique
|
|
US5102417A
(en)
|
1985-11-07 |
1992-04-07 |
Expandable Grafts Partnership |
Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
|
|
US4800882A
(en)
|
1987-03-13 |
1989-01-31 |
Cook Incorporated |
Endovascular stent and delivery system
|
|
US4886062A
(en)
|
1987-10-19 |
1989-12-12 |
Medtronic, Inc. |
Intravascular radially expandable stent and method of implant
|
|
WO1990013332A1
(en)
|
1989-05-11 |
1990-11-15 |
Cedars-Sinai Medical Center |
Stent with sustained drug delivery
|
|
EP0470246B1
(en)
|
1990-02-28 |
1995-06-28 |
Medtronic, Inc. |
Intralumenal drug eluting prosthesis
|
|
US5419760A
(en)
|
1993-01-08 |
1995-05-30 |
Pdt Systems, Inc. |
Medicament dispensing stent for prevention of restenosis of a blood vessel
|
|
US5429634A
(en)
|
1993-09-09 |
1995-07-04 |
Pdt Systems |
Biogenic implant for drug delivery and method
|
|
US6774278B1
(en)
|
1995-06-07 |
2004-08-10 |
Cook Incorporated |
Coated implantable medical device
|
|
DE19539091A1
(de)
|
1995-10-20 |
1997-04-24 |
Thomae Gmbh Dr K |
5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
|
|
CA2229617A1
(en)
|
1995-10-20 |
1997-05-01 |
Dr. Karl Thomae Gmbh |
5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
US5833651A
(en)
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
GT200100147A
(es)
|
2000-07-31 |
2002-06-25 |
|
Derivados de imidazol
|
|
US6756385B2
(en)
|
2000-07-31 |
2004-06-29 |
Pfizer Inc. |
Imidazole derivatives
|
|
WO2002024656A1
(en)
|
2000-09-22 |
2002-03-28 |
Nihon Nohyaku Co., Ltd. |
N-(4-pyrazolyl)amide derivatives, chemicals for agricultural and horticultural use, and usage of the same
|
|
US7589199B2
(en)
*
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US20050256130A1
(en)
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7842693B2
(en)
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US6770729B2
(en)
|
2002-09-30 |
2004-08-03 |
Medtronic Minimed, Inc. |
Polymer compositions containing bioactive agents and methods for their use
|
|
WO2004099156A1
(en)
|
2003-05-01 |
2004-11-18 |
Bristol-Myers Squibb Company |
Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
|
|
US7381714B2
(en)
|
2005-05-19 |
2008-06-03 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
DK1906965T3
(en)
|
2005-06-22 |
2015-08-03 |
Chemocentryx Inc |
Azaindazol compounds and methods of use thereof
|
|
FR2887450B1
(fr)
|
2005-06-23 |
2007-08-24 |
Rhodia Chimie Sa |
Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
|
|
WO2007026834A1
(ja)
|
2005-09-01 |
2007-03-08 |
Kumiai Chemical Industry Co., Ltd. |
ピラゾール誘導体及び農園芸用除草剤
|
|
US7576218B2
(en)
|
2005-10-11 |
2009-08-18 |
Chemocentryx, Inc. |
4-phenylpiperdine-pyrazole CCR1 antagonists
|
|
US20090252779A1
(en)
|
2006-06-22 |
2009-10-08 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
ES2430821T3
(es)
|
2006-10-10 |
2013-11-21 |
Amgen Inc. |
Compuestos de N-arilpirazol para usar contra la diabetes
|
|
US20100113776A1
(en)
*
|
2006-12-14 |
2010-05-06 |
Taisho Pharmaceutical Co.,Ltd. |
Pyrazole derivative
|
|
US7786157B2
(en)
|
2007-03-16 |
2010-08-31 |
Chemocentryx, Inc. |
OXO-imidazolidines as modulators of chemokine receptors
|
|
WO2008147815A1
(en)
*
|
2007-05-22 |
2008-12-04 |
Chemocentryx, Inc. |
3-(imidazolyl)-pyrazolo[3,4-b]pyridines
|
|
WO2010030815A1
(en)
*
|
2008-09-11 |
2010-03-18 |
Chemocentryx, Inc. |
4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
EP3663295A1
(en)
|
2007-06-22 |
2020-06-10 |
Eli Lilly And Co. |
2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
|
|
PL2221298T3
(pl)
*
|
2007-11-13 |
2014-05-30 |
Taisho Pharmaceutical Co Ltd |
Pochodne fenylopirazolu
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2009137338A1
(en)
|
2008-05-06 |
2009-11-12 |
Boehringer Ingelheim International Gmbh |
Pyrazole compounds as ccr1 antagonists
|
|
US20120108614A1
(en)
|
2008-05-14 |
2012-05-03 |
Chong Jayhong A |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
MX2011003195A
(es)
|
2008-09-26 |
2011-08-12 |
Dana Farber Cancer Inst Inc |
Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
|
|
EP2352730A4
(en)
|
2008-11-07 |
2012-04-25 |
Lundbeck & Co As H |
BIOLOGICAL ACTIVE AMIDE
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
GB0915892D0
(en)
|
2009-09-10 |
2009-10-14 |
Smithkline Beecham Corp |
Compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
LT2785375T
(lt)
|
2011-11-28 |
2020-11-10 |
Merck Patent Gmbh |
Anti-pd-l1 antikūnai ir jų panaudojimas
|
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
|
JP2015512910A
(ja)
|
2012-03-29 |
2015-04-30 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
ヒトｐｄ１のｂｃループに由来する免疫調節性環状化合物
|
|
WO2013173223A1
(en)
|
2012-05-15 |
2013-11-21 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR102129636B1
(ko)
|
2012-05-31 |
2020-07-03 |
제넨테크, 인크. |
Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
WO2014089498A1
(en)
|
2012-12-07 |
2014-06-12 |
Optionality Holdings, Inc. |
Compliance service
|
|
RU2666730C2
(ru)
|
2012-12-07 |
2018-09-12 |
Кемосентрикс, Инк. |
Диазольные лактамы
|
|
CN104918921B
(zh)
|
2012-12-21 |
2017-09-22 |
凯莫森特里克斯股份有限公司 |
二唑酰胺
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
SG11201600310QA
(en)
|
2013-07-16 |
2016-02-26 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
JP6586087B2
(ja)
|
2013-08-20 |
2019-10-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
|
|
WO2015034820A1
(en)
|
2013-09-04 |
2015-03-12 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
SG11201601685TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
Cyclic peptidomimetic compounds as immunomodulators
|
|
ES2675027T3
(es)
|
2013-09-06 |
2018-07-05 |
Aurigene Discovery Technologies Limited |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
|
SG11201601679TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
AU2015267051B2
(en)
|
2014-05-27 |
2022-03-17 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
MX380553B
(es)
|
2014-09-11 |
2025-03-12 |
Bristol Myers Squibb Co |
Inhibidores macrocíclicos de las interacciones proteína/proteína de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1.
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
CU20170117A7
(es)
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Tech Ltd |
COMPUESTOS TIADIAZOL y 1,3,4-OXADIAZOL 3-SUSTITUIDOS COMO INMUNOMODULADORES
|
|
SG11201706902SA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
CA3220902A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
CU20170116A7
(es)
|
2015-03-10 |
2018-06-05 |
Aurigene Discovery Tech Ltd |
Compuestos cíclicos terapéuticos como inmunomoduladores
|
|
JP2018507885A
(ja)
|
2015-03-10 |
2018-03-22 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
BR112018070361A2
(pt)
|
2016-04-07 |
2019-01-29 |
Chemocentryx Inc |
redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
|